Announcements Trials

Browse Landscape

Phase

Status

Completed 2 Unknown 1 Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Leiomyoma 2 Breast Neoplasms 2 Vomiting 1 Vascular Malformations 1 Uterine Neoplasms 1 Resectable Pancreatic Ductal Adenocarcinoma 1 Prostatic Neoplasms 1 Pregnancy Complications 1 Postoperative Hemorrhage 1 Postoperative Complications 1 Neoplasms 1 Nausea 1 Myofibroma 1 Myasthenia Gravis 1 Microbiota 1 Melanoma 1 Lymphangioma 1 Infertility, Female 1 Hepatitis B 1 Hand-Foot Skin Reaction (HFSR) 1 Glioblastoma 1 Erectile Dysfunction 1 Carcinoma, Non-Small-Cell Lung 1 Blood Loss, Surgical 1

Interventions

Nivolumab 25 pembrolizumab 20 Ipilimumab 15 toripalimab 12 Temozolomide 11 Biopsy 8 Dacarbazine 7 Cyclophosphamide 6 Blood Specimen Collection 6 trametinib 5 fludarabine 5 dabrafenib 5 camrelizumab 5 atezolizumab 5 Gene Expression Profiling 5 Chemotherapy, Adjuvant 5 durvalumab 4 binimetinib 4 aldesleukin 4 Interleukin-2 4 Injections 4 Carboplatin 4 tislelizumab 3 palbociclib 3 encorafenib 3 apatinib 3 Sorafenib 3 Paclitaxel 3 Introns 3 Drug Therapy 3

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Unknown × Melanoma × Tablets × Clear all

NCT05370807 2023-10-24

RegoMel

Universitair Ziekenhuis Brussel

Phase 2 Unknown

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡